オプションチェーンは、Thermo Fisher Scientificの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Thermo Fisher Scientificの市場センチメントを評価します。.

Thermo Fisher Scientific (NYSE:TMO) 株価情報, オプションチェーン

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMTOM N.V. ORD

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Trimol Group Inc

THERMO FISHER SCIENTIFIC ORD

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 6.7% on an annualized basis producing an average annual return of 18.36%. Currently, Thermo Fisher Scientific has a market capitalization of $212.03 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,242.44 today based on a price of $555.47 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730836834_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the options we uncovered, 13 are puts, for a total amount of $444,315, and there was 1 call, for a total amount of $35,800.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $520.0 and $570.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale trades within a strike price range from $520.0 to $570.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730139332_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.9</td>
<td>$8.3</td>
<td>$8.05</td>
<td>$530.00</td>
<td>$72.4K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.13</td>
<td>$530.00</td>
<td>$49.5K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">264</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.08</td>
<td>$530.00</td>
<td>$41.2K</td>
<td style="text-align: right;">201</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$72.8</td>
<td>$70.4</td>
<td>$71.6</td>
<td>$550.00</td>
<td>$35.8K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$11.6</td>
<td>$9.5</td>
<td>$10.48</td>
<td>$560.00</td>
<td>$31.5K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">30</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
In light of the recent options history for Thermo Fisher Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Thermo Fisher Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 472,526, with TMO's price down by -0.34%, positioned at $552.47.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $637.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Thermo Fisher Scientific, which currently sits at a price target of $610. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $630. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Thermo Fisher Scientific with a target price of $660. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $665. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $622. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Market Whales and Their Recent Bets on TMO Options

Bernstein analyst Eve Burstein maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Market Perform and lowers the price target from $625 to $620.

Price Target

Analyst Ratings

Bernstein Maintains Market Perform on Thermo Fisher Scientific, Lowers Price Target to $620

RBC Capital analyst Conor McNamara maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $767 to $718.

RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $718

WIIM

Thermo Fisher Scientific shares are trading lower after multiple firms lowered their respective price targets on the stock.

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $680 to $665.

Stifel Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $665

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $630 to $620.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $620

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $670 to $660.

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $660

Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $632 to $622.

Baird Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $622

STOCK RISES ALMOST 2%
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="806" height="789" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM.png" alt="" class="wp-image-2678" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM.png 806w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM-300x294.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/23201141/Screen-Shot-2024-10-23-at-4.12.36-PM-768x752.png 768w" sizes="(max-width: 806px) 100vw, 806px" /></figure>
Thermo Fisher Scientific, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:33 AM on October 23rd , a significant trading signal occurred for Thermo Fisher Scientific, Inc. as it demonstrated a Power Inflow at a price of $567.46. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TMO&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TMO&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and studies both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted by active traders as a bullish signal.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TMO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $567.46. The returns on the High price ($577.02) and Close price ($576.57) after the Power Inflow were respectively 1.7% and 1.6%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert

Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest <a href="https://www.benzinga.com/earnings">batch of corporate earnings.</a>
Both equities and commodities took a hit on Wednesday, while the U.S. dollar gained strength, attracting investor flows as traders moved to safer cash positions.
The U.S. dollar index, as tracked by the the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.5%, reaching levels last seen in late July. 
At midday in New York, the S&amp;P 500 was down 0.7%, attempting to hold support around the 5,800-point level. The Dow Jones also dropped 0.7%, and tech stocks, along with small caps, fared worse, sliding by 0.9%.
On the data front, mortgage applications declined for the fourth straight week, reflecting continued pressure <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41488744/mortgage-applications-fall-for-fourth-straight-week-as-high-rates-squeeze-homebuy">from elevated borrowing costs.</a>
Existing home sales fell by 1% in September to a seasonally adjusted annualized rate of 3.84 million, the lowest level since October 2010. This follows an upwardly revised 3.88 million in August and missed forecasts of 3.9 million.
Despite weak housing data, real estate stocks showed surprising resilience. The Vanguard Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNQ#NYSE">VNQ</a>) and the SPDR Homebuilders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHB#NYSE">XHB</a>) moved higher after two straight sessions of losses.
Gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), fell more than 1%, pulling mining stocks down with it. Silver plummeted over 3%, retreating from 12-year highs reached on Tuesday.
Oil prices slipped by 1%, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) tumbled 2%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,815.02</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,625.59</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,196.24</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated 12:00 p.m. ET </figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.6% to $579.72.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.7% lower to $426.41.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1% to $491.16.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% $219.80.</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 0.6%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 2.4% after reporting a worse-than-expected losses<a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation"> last quarter</a>.</li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), up 3.5%.</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), up 3.9%.</li>
<li>Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), down over 7%.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>), up over 6%.</li>
<li>Manhattan Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), down over 7%.</li>
<li>East West Bancorp. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), up over 7%.</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), down over 13%.</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), down 2.2%. </li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), down 2.9%.</li>
<li>NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), down 0.1%. </li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), up 3.8%. </li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), down 3.7%. </li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), down 0.9%. </li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), down 1.6%. </li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), down 2.6%. </li>
<li>Vertiv Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), down 2.8%. </li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>), down 4.8%. </li>
</ul>
Large-cap companies reporting earnings after the close include Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>). 
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/10/41455678/gold-on-track-for-best-year-since-1979-veteran-investor-says-sell-bonds-buy-gold">Gold On Track For Best Year Since 1979: Veteran Investor Says &#8216;Sell Bonds, Buy Gold&#8217;</a></li>
</ul>

Equities

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

EWBC

LRCX

MANH

ODFL

TMUS

TSLA

PowerShares DB US Dollar Index Bullish Fund

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?

On Wednesday,&nbsp;Thermo Fisher Scientific Inc.&nbsp;(NYSE:&nbsp;TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.64 billion</a>.
Revenue growth, organic revenue growth, and core organic revenue all improved sequentially from Q2 and were flat compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41482387/thermo-fisher-scientific-reports-third-quarter-2024-results" rel="noreferrer noopener">prior-year quarter</a>.
Revenue from the Life Sciences Solutions Segment declined by 1.9% to&nbsp;$2.39 billion. Analytical Instruments Segment sales were up 3.1% to $1.81 billion.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184148/novo-nordiskastrazenecas-manufacturing-partner-thermo-fisher-questioned-over-manufacturing-lapses" rel="noreferrer noopener">Novo Nordisk/AstraZeneca&#8217;s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses</a>.
Specialty Diagnostics Segment revenues increased 4.2% to $1.13 billion, and Laboratory Products and Biopharma Services segment sales were almost flat at $5.74 billion.
Adjusted EPS of $5.28 beat the consensus of $5.25 but fell from $5.69 a year ago.&nbsp;
Adjusted operating income for the third quarter of 2024 was $2.36 billion, compared with $2.56 billion in the year-ago quarter. Adjusted operating margin was 22.3%, compared with 24.2% in the third quarter of 2023.
&#8220;We are pleased to deliver strong financial results in the third quarter, reflecting another quarter of sequential improvement in growth,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
Casper added, &#8220;Looking ahead, we&#8217;re in a great position to deliver on our 2024 objectives&#8230;&#8221;
Guidance:&nbsp;Thermo Fisher&nbsp;reaffirms its 2024 sales guidance of $42.4 billion—$43.3 billion, compared to the consensus of $42.91 billion.
The life science company revised its adjusted EPS guidance to $21.35-$22.07, compared to its <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">previous guidance of $21.29-$22.07</a> and consensus of $21.72.
Price Action: TMO stock traded lower by 2.17% to $573.66 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular" target="_blank" rel="noreferrer noopener">Industry Leader Thermo Fisher&#8217;s Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Health Care

Movers

General

Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives

Thermo Fisher Reaffirms Its 2024 Revenue Guidance Of $42.4B-$43.3B Versus Consensus Of $42.91B

Thermo Fisher Raises Its 2024 Adjusted EPS Guidance To $21.35-$22.07 Versus Its Previous Guidance Of $21.29-$22.07 And Consensus Of $21.72

Thermo Fisher Scientific Q3 2024 Adj. EPS $5.28 Beats $5.25 Estimate, Sales $10.598B Miss $10.638B Estimate

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Thermo Fisher Scientific to report an earnings per share (EPS) of $5.25.
The market awaits Thermo Fisher Scientific's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.25, leading to a 3.44% increase in the share price on the subsequent day.
Here's a look at Thermo Fisher Scientific's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.12</td>
<td>4.71</td>
<td>5.64</td>
<td>5.61</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.37</td>
<td>5.11</td>
<td>5.67</td>
<td>5.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729609380_0.png" alt="eps graph" />
<h3>Tracking Thermo Fisher Scientific's Stock Performance</h3>
Shares of Thermo Fisher Scientific were trading at $595.37 as of October 21. Over the last 52-week period, shares are up 36.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Thermo Fisher Scientific</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Thermo Fisher Scientific.
The consensus rating for Thermo Fisher Scientific is Outperform, derived from 15 analyst ratings. An average one-year price target of $665.4 implies a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Danaher, IQVIA Hldgs and Agilent Technologies, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Danaher is favoring an Outperform trajectory, with an average 1-year price target of $283.42, suggesting a potential 52.4% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for IQVIA Hldgs, with an average 1-year price target of $268.5, indicating a potential 54.9% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Agilent Technologies, with an average 1-year price target of $148.78, suggesting a potential 75.01% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Danaher, IQVIA Hldgs and Agilent Technologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermo Fisher Scientific</td>
<td>Outperform</td>
<td>-1.37%</td>
<td>$4.35B</td>
<td>3.33%</td>
</tr>
<tr>
<td>Danaher</td>
<td>Outperform</td>
<td>-2.86%</td>
<td>$3.43B</td>
<td>1.76%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Outperform</td>
<td>2.31%</td>
<td>$1.33B</td>
<td>5.56%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$855M</td>
<td>4.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Thermo Fisher Scientific ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Get to Know Thermo Fisher Scientific Better</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Unraveling the Financial Story of Thermo Fisher Scientific</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Thermo Fisher Scientific faced challenges, resulting in a decline of approximately -1.37% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Thermo Fisher Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Thermo Fisher Scientific's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.58%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.75.
<a href="https://www.benzinga.com/quote/TMO/earnings">To track all earnings releases for Thermo Fisher Scientific visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Thermo Fisher Scientific

Redburn Atlantic initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy rating and announces Price Target of $680.

Initiation

Redburn Atlantic Initiates Coverage On Thermo Fisher Scientific with Buy Rating, Announces Price Target of $680

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Oct. 11:
NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): The utility company saw headlines during the week related <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo">to Hurricane Milton</a> and power outages in the state of Florida, which likely increased interest from Benzinga readers. 
The company owns Florida Power &amp; Light, which has more than six million customers in Florida. A report said <a href="https://www.benzinga.com/news/24/10/41266095/hurricane-milton-knocks-out-power-for-over-2m-in-florida-nextera-energy-duke-energy-and-tampa-electr">over 900,000 lost power</a> after Hurricane Milton struck the state. While the power outages could have a short-term negative impact on the company, NextEra is also the owner of a renewable energy segment and should be able to recover from the hurricane impact over the long term.
The company is set to report third-quarter financial results on Oct. 23, which could provide more commentary on the storm's impact. The company has beaten analyst estimates for earnings per share in nine of the past 10 quarters and beaten revenue estimates in six of the past 10 quarters.
Shares were slightly up the past week, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png" alt="" class="wp-image-591824" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Monolithic Power Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): A chipmaker specializing in power management systems, Monolithic Power Systems continues to see elevated interest from Benzinga readers. 
The company appeared on the Stock Whisper Index<a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet"> two weeks ago</a> after Stifel increased its price target from $1,000 to $1,100 while maintaining a Buy rating.
The company is expected to report third-quarter financial results in October. The chipmaker has beaten analyst estimates for earnings per share in more than 10 straight quarters and beaten revenue estimates from analysts in six straight quarters. A strong earnings report could send shares higher.
Monolithic shares were up more than 2% on the week and are up over 57% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png" alt="" class="wp-image-591826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): The software company and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) owner is no stranger to the Stock Whisper Index, making frequent appearances on the list thanks to growing interest in cryptocurrency and the company's strategy of buying Bitcoin with cash and by raising funds.
The company recently <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">announced the newest release</a> of MicroStrategy ONE, which includes integrations with Microsoft Teams and has new features for its AI bot. While many know the company as a major Bitcoin owner, MicroStrategy's software segment helps bring in cash flow to fuel the Bitcoin purchases.
MicroStrategy&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857237/microstrategy-stock-climbs-after-bitcoin-purchase-heres-how-much-btc-michael-saylors-compa" target="_blank" rel="noreferrer noopener">recently announced it bought</a>&nbsp;$1.1 billion worth of Bitcoin bringing its total up to 244,800 Bitcoin. The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919378/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases" target="_blank" rel="noreferrer noopener">recently raised</a>&nbsp;over $800 million to redeem $500 million in senior secured notes and to buy additional Bitcoin.
MicroStrategy began buying Bitcoin in August 2020 and will continue to add more Bitcoin, as co-founder and Executive Chairman&nbsp;Michael Saylor&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/22/06/27865236/exclusive-michael-saylors-microstrategy-is-married-to-bitcoin-everything-else-in-the-world" target="_blank" rel="noreferrer noopener">previously told Benzinga.</a>
&#8220;We have a simple strategy and our strategy is we just acquire Bitcoin, and we hold the Bitcoin,&#8221; Saylor told Benzinga.
New leveraged and inverse ETFs targeting MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40930553/microstrategy-2x-leveraged-inverse-etfs-are-here-offer-unparalleled-access-to-microstrateg">also recently launched, </a>which could increase interest in the company.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png" alt="" class="wp-image-591827" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-768x385.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>): The natural gas company saw increased interest from Benzinga readers over the trading week. The surge in interest could be related to natural gas being volatile related to increased tension in the Middle East. 
Cheniere Energy will report third-quarter financial results on Oct. 31. The company has beaten analyst estimates for earnings per share in six of the past seven quarters and beaten revenue estimates from analysts in eight of the past 10 quarters.
Cheniere shares have traded near 52-week highs, as seen on the chart below. The stock is up 13% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="498" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png" alt="" class="wp-image-591828" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-768x383.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): The scientific instruments and life sciences company saw a surge in interest from readers during the week. 
The increased attention could be related to Stephens <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular">initiating coverage on the stock </a>with an Overweight rating and $680 price target. The analyst sees the company benefiting from contract services and the surging demand for GLP-1 weight loss drugs. 
Stephens also highlighted the company's disciplined M&amp;A strategy to help with long-term growth. Evercore ISI Group also recently<a href="https://www.benzinga.com/quote/TMO/analyst-ratings"> raised the price target</a> on the stock from $605 to $630 while maintaining an Outperform rating.
The company is set to report third-quarter financial results on Oct. 23. Thermo Fisher has beaten analyst estimates for earnings per share in seven of the past 10 quarters and beaten revenue estimates from analysts in seven of the past 10 quarters.
Thermo Fisher shares are up 0.5% over the past five days and up around 10% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png" alt="" class="wp-image-591830" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 13</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/09/40962321/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 20</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 27</a></li>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 4</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a></li>
</ul>

Exclusives

MPWR

MSTR

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 5 years by 2.11% on an annualized basis producing an average annual return of 16.12%. Currently, Thermo Fisher Scientific has a market capitalization of $226.51 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 5 years ago, it would be worth $2,133.77 today based on a price of $593.41 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728322209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 12.9% since its last report. The company recently reported that it has 3.99 million shares sold short, which is 1.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728312314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 5.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TMO) - Analyzing Thermo Fisher Scientific's Short Interest

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price targ...

Thermo Fisher (TMO) Gets a Buy from RBC Capital

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $665.00. The ...

Stifel Nicolaus Reaffirms Their Buy Rating on Thermo Fisher (TMO)

RBC Capital lowered the firm's price target on Thermo Fisher (TMO) to $718 from $767 but keeps an Outperform rating on the shares. The company's Q3...

Thermo Fisher price target lowered to $718 from $767 at RBC Capital

Analyst Catherine Ramsey Schulte of Robert W. Baird reiterated a Buy rating on Thermo Fisher (TMO – Research Report), reducing the price target to ...

Thermo Fisher's Strategic Positioning and Growth Potential Reinforce Buy Rating

Thermo Fisher (TMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda from L...

Thermo Fisher's Resilience and Long-Term Potential Highlighted Amid Challenges: Buy Rating Reaffirmed

Analyst Tejas Savant of Morgan Stanley maintained a Buy rating on Thermo Fisher (TMO – Research Report), reducing the price target to $670.00. Teja...

Thermo Fisher's Resilient Growth and Strategic Management Earns Buy Rating

Parnassus Growth Equity Fund Q3 2024 Commentary

Post-Election Day Trade List: 10 S&P 500 Stocks At Risk

SA Asks: How will the U.S. election results impact healthcare stocks?

Seer (SEER) announced a co-marketing and sales agreement with Thermo Fisher (TMO) to jointly promote Seer's Proteograph Product Suite alongside The...

Seer, Thermo Fisher enter co-marketing and sales agreement

AAPL

ABBV

ABNB

ADYEY

ADYYF

AKAM

AMAT

AMGN

CHTR

CSGP

FHLC

INTU

MELI

MSCI

MSFT

NVDA

PCOR

QCOM

SEER

TEVA

Press Releases

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Thermo Fisher Scientific Reports Second Quarter 2024 Results

Small Cap

Opinion

Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth

Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024

Thermo Fisher Scientific Hosts 2024 Investor Day

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential"

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2024

Thermo Fisher Scientific Reports Third Quarter 2024 Results

BATL

BDTX

BNZI

BVAXF

CSE:BIOV

HSCS

KAVL

NEOG

PRSO

RHHBY

SEEL

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Thermo Fisher Scientific

Thermo Fisher Scientific (TMO) オプション

Thermo Fisher Scientific (NYSE:TMO) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル